Skip to content
DataLookout
Menu

NCT07015853

ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation

StatusRecruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved at least 4 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 6 more changesShow less
    • Start date: Jun 2026 to Dec 2026
    • Eligibility criteria expanded, about 34 words
    • Primary and study completion pushed from Jul 2033 to Dec 2033
    • Secondary endpoints: details revised at 4 of 4 entries
    • Site details revised
    • Collaborators: details revised at 1 of 2 entries
  2. Notable Primary and study completion dates: Dec 2032 to Jul 2033
    • Start date: Sep 2025 to Jun 2026
    v3
  3. Notable Start date: Jul 2025 to Sep 2025
    • Primary and study completion dates: Oct 2032 to Dec 2032
    v2
  4. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Overall Response Rate (ORR)
Timeframe: From start of study treatment until subject proceeds to standard of care treatment, up to 2 years.

Secondary (4)

Number of Adverse Events Related to Study Treatment
Progression-free survival (PFS)
Overall Survival (OS)
Duration of Response (DoR)

Arms and interventions

Pembrolizumab, Radiotherapy, AxatilimabExperimental

Pembrolizumab (MK-3475), 200 mg IV Q3W starting at C1D1/Week 1 for up to 2 years, until disease progression, or treatment intolerance. Radiotherapy, 8 Gy x 3 fractions over 3 consecutive days at C1D8/Week 2; Axatilimab (SNDX-6352; INCA034176), 1 mg/kg, IV, Q2W starting 1 week post- RT C1D15/Week 3 until disease progression or treatment intolerance.

Drugs: Pembrolizumab, Axatilimab

Radiation: Radiotherapy

Sites

1 site in 1 country

  • Cedars-Sinai Medical CenterLos Angeles, California, United States